



# 3rd International Electronic Conference on Medicinal Chemistry

1-30 November 2017

chaired by Dr. Jean Jacques Vanden Eynde



## Organocatalytic Synthesis of Chiral 1,4-Dihydropyridines with Potential Biological Properties

Fernando Auria-Luna<sup>1,\*</sup>, M. Eugenia Marqués-López<sup>1</sup>, M. Concepción Gimeno<sup>2</sup>, and Raquel P. Herrera<sup>1</sup>

<sup>1</sup>Laboratorio de Organocatálisis Asimétrica, Departamento de Química Orgánica, Facultad de Ciencias, Instituto de Síntesis Química y Catálisis Homogénea (ISQCH), CSIC-Universidad de Zaragoza, C/Pedro Cerbuna 12, 50009, Zaragoza.


<sup>2</sup>Departamento de Química Inorgánica, Facultad de Ciencias, Instituto de Síntesis Química y Catálisis Homogénea (ISQCH), CSIC-Universidad de Zaragoza, C/Pedro Cerbuna 12, 50009, Zaragoza.

\* Corresponding author: [ferauria@unizar.es](mailto:ferauria@unizar.es)



# Organocatalytic Synthesis of Chiral 1,4-Dihydropyridines with Potential Biological Properties

## Graphical Abstract



3rd International Electronic Conference  
on Medicinal Chemistry  
1-30 November 2017

sponsors:



pharmaceuticals

## Abstract:

The 1,4-dihydropyridine core is a widely studied privileged scaffold. Molecules containing this structure are well known calcium channel blockers and are being used already as drugs in the treatment of heart disease. Moreover, recent advances have demonstrated their potential to act against many other diseases. The recent research concerning their activity as multidrug-resistance reversing agents should be highlighted. In the chemistry field, they are soft reducing agents and have been used in asymmetric reductions.

As shown before, these molecules contain a chiral center in their C4 position. Nowadays, it is well known that living matter can discern between stereoisomers of the same compound. Nevertheless, there are scarce examples of procedures leading to enantiomerically enriched 1,4-DHPs, most of them being based on the use of chiral auxiliaries or chiral resolutions. Finding more environmental-friendly processes is also an interesting matter in chemistry, organocatalytic procedures are a perfect tool to achieve this goal.

Herein, we report our recent advances in the development of new organocatalytic methodologies to produce enantiomerically enriched 1,4-DHPs. Interestingly, one of them brings out another privileged scaffold, such as the oxindole motif. Our methodologies could be perfect keystones leading to further research on the biological properties of these promising compounds.

**Keywords:** 1,4-dihydropyridines; 1,4-DHPs; organocatalysis; cinchona; (thio)ureas






3rd International Electronic Conference  
on Medicinal Chemistry  
1-30 November 2017

sponsors:   pharmaceuticals

# Introduction



**DRUG DISCOVERY**



3rd International Electronic Conference  
on Medicinal Chemistry  
1-30 November 2017

sponsors:



pharmaceuticals

# Introduction

## CATALYSIS AS A KEY TOOL

### *GREEN CHEMISTRY*


“The invention, design and application of chemical products and processes to reduce or eliminate the use and the production of harmful substances.”

*IUPAC*

### *ORGANOCATALYSIS*

“The acceleration of chemical reactions with a substoichiometric amount of organic molecules, which do not contain a metal element.”

*Organocatalysis* (Eds.: M. T. Reetz, B. List, S. Jaroch, H. Weinmann). Springer, Berlin-Heidelberg, New York, 2007.



Organocatalytic step of the enantioselective synthesis of (S)-Warfarin




3rd International Electronic Conference  
on Medicinal Chemistry  
1-30 November 2017


sponsors:   pharmaceuticals

# Introduction


## Privileged scaffolds




Indol




**Oxipertine**  
Antidepressant




Quinoline



**Broxiquinoline**  
Antiseptic




Dihydropyridine




**Nifedipine**  
Antihypertensive


## NATURAL PRODUCTS



**Nostodione A**  
Mitotic spindle poison



**Quinine**  
Antimalarial



**NADH**  
Coenzyme

*Curr. Opin. Chem. Biol.* **2010**, *14*, 347.



3rd International Electronic Conference  
on Medicinal Chemistry  
1-30 November 2017


sponsors:




pharmaceuticals

# Introduction


*Classic activity of DHPs: Ca Channel Blockers*




**Felodipine**



**Nitredipine**



**Barnidipine**




**Amlodipine**



# Introduction


## *Multidrug-resistance reversing agents*

Classical MDR



Morris, M. E. *J. Pharm. Sci.* **2005**,  
94, 2256-2265.

Atypical MDR



Mehdipour, A.R. *et al. Chem. Biol. Drug Des.*  
**2007**, 70, 337-346.




3rd International Electronic Conference  
on Medicinal Chemistry  
1-30 November 2017

sponsors:   pharmaceuticals




# Introduction

## *DHPs, more than Ca channel blockers*




ANTITUBERCULAR

Desai, B. *et al. Bioorg. Med. Chem.* **2001**, *9*, 1993-1998.



ANTITUMOR

Surendra Kumar, R. *Indian J. Chem. Sect. B.* **2011**, *50*, 1140-1144.



ALZHEIMER TREATMENT

López-Arrieta, J.M. and Birks, J. *Cochrane Database Syst. Rev.* **2002**, *3* CD000147.



3rd International Electronic Conference  
on Medicinal Chemistry  
1-30 November 2017

sponsors:






pharmaceuticals

# Introduction



*Chirality on farmacology and 1,4-DHPs*




## DIFFERENTIATION



**TERATOGENIC**



**SEDATIVE**



**SCARCE EXAMPLES OF  
ENANTIOSELECTIVE  
PROCEDURES**

Organocatalytic synthesis of chiral 1,4-dihydropyridines.

Herrera, R. P. *et al*

*Adv. Synth. Catal.* **2017**, 359, 2161-2175.




3rd International Electronic Conference  
on Medicinal Chemistry  
1-30 November 2017

sponsors:




pharmaceuticals

## Results and discussion




Herrera, R. P. *et al* *Molecules*, **2015**, *20*, 15807-15826.


### SPIROOXINDOLE



horsfiline (X = MeO)  
coerulescine (X = H)



(+)-elacomine



alstonisine



3rd International Electronic Conference  
on Medicinal Chemistry  
1-30 November 2017


sponsors:













pharmaceuticals

# Results and discussion

## Reaction scope




Up to 82% yield  
Up to 58% ee




# Results and discussion

**X ray  
structure**



Prof. Gimeno, M. C. (ISQCH, CSIC)

**Mechanistic  
proposal**




3rd International Electronic Conference  
on Medicinal Chemistry  
1-30 November 2017

sponsors:





pharmaceuticals

## Results and discussion



R. P. Herrera y col. *J. Org. Chem.*  
2017, 82, 5516-5523.



3rd International Electronic Conference  
on Medicinal Chemistry  
1-30 November 2017


sponsors:




pharmaceuticals

# Results and discussion


## Reaction scope




Up to 99% yield  
Up to 82% ee




99% yield  
74% ee




96% yield  
74% ee



97% yield  
76% ee




62% yield  
74% ee




71% yield  
73% ee

Ethyl ester derivatives


Methyl ester derivatives




88% yield  
82% ee




76% yield  
62% ee




69% yield  
74% ee




89% yield  
64% ee




99% yield  
77% ee




21% yield  
80% ee




82% yield  
74% ee




36% yield  
72% ee




43% yield  
76% ee



79% yield  
82% ee



22% yield  
72% ee



15% yield  
76% ee



3rd International Electronic Conference  
on Medicinal Chemistry  
1-30 November 2017


sponsors:



pharmaceuticals


# Results and discussion

**X ray  
structure**



Prof. Gimeno, M. C. (ISQCH, CSIC)

**Mechanistic  
proposal**



3rd International Electronic Conference  
on Medicinal Chemistry  
1-30 November 2017


sponsors:



pharmaceuticals



## Conclusions



- ✓ Pioneering catalytic strategies leading to 1,4-DHPs.
- ✓ Mild conditions and operational simplicity.
- ✓ Promising results.
- ✓ Great structural diversity.



# Acknowledgments



DGA group (E-104) Organocatálisis Asimétrica. <https://hoca.unizar.es>



Departamento de  
Química Orgánica  
Universidad Zaragoza

1542



Escuela Politécnica  
Superior - Huesca  
Universidad Zaragoza



Instituto de Síntesis Química y Catálisis Homogénea



CSIC  
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS



Universidad  
Zaragoza

1542



Facultad de Ciencias  
Universidad Zaragoza



3rd International Electronic Conference  
on Medicinal Chemistry  
1-30 November 2017

sponsors:



pharmaceuticals